Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Next Previous
X
Search
Trial Profile

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alogliptin (Primary) ; Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Dulaglutide (Primary) ; Empagliflozin (Primary) ; Ertugliflozin (Primary) ; Exenatide (Primary) ; Glibenclamide (Primary) ; Glimepiride (Primary) ; Glipizide (Primary) ; Insulin degludec (Primary) ; Insulin detemir (Primary) ; Insulin glargine (Primary) ; Insulin suspension isophane (Primary) ; Linagliptin (Primary) ; Liraglutide (Primary) ; Saxagliptin (Primary) ; Semaglutide (Primary) ; Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms BESTMED

    • Most Recent Events

    • 23 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top